Aardvark

GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 15, 2023
Research, Therapy, Interim, Natural killer T cell, Insurance, Patient, Idiopathic pulmonary fibrosis, IPF, Abuse, SLE, Idiopathic disease, Conference, Lupus nephritis, Injury, Aardvark, NKT, GRI, Doctor of Philosophy, Inflammation, Fibrosis, Rare-earth element, Pharmaceutical industry, Vaccine, Immunology, Frontiers

LA JOLLA, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Importantly, we believe 2024 will be the year of data for GRI Bio,” commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio.
  • GRI Bio’s lead program, GRI-0621, is a small molecule RAR-βɣ dual agonist that inhibits the activity of human type 1 iNKT cells.
  • Research and development expenses were $2.2 million and $0.2 million for the nine months ended September 30, 2023 and 2022, respectively.
  • As of September 30, 2023, the Company had cash and cash equivalents of approximately $3.5 million.

GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR

Retrieved on: 
Wednesday, August 23, 2023
Dextroamphetamine, Abuse, Clinical trial, ADHD, Prader–Willi syndrome, Doctor of Philosophy, Vallon, Attention deficit hyperactivity disorder, GRI, European, FDA, Therapy, Natural killer T cell, Pharmaceutical industry, Aardvark

LA JOLLA, CA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the Company has entered into an asset purchase agreement pursuant to which Aardvark Therapeutics, Inc. (“Aardvark”) will acquire certain assets and intellectual property of the Company that pertain to ADAIR (Abuse Deterrent Amphetamine Immediate Release). Aardvark intends to utilize the ADAIR formation technology for the development of certain follow-on pipeline programs.

Key Points: 
  • Aardvark intends to utilize the ADAIR formation technology for the development of certain follow-on pipeline programs.
  • Exclusive license rights to develop and commercialize ADAIR in Europe and the UK were previously licensed to Medice Arzneimittel Pütter GmbH, a leader in the European ADHD market.
  • GRI Bio will receive a modest up-front payment and the potential to earn milestone payments for achievements in development and commercialization from Aardvark up to approximately $80 million.
  • We believe in the potential of ADAIR and are pleased to have it continue on in its development at Aardvark,” commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio.

Aardvark Therapeutics Announces FDA Orphan Drug Designation Granted to ARD-101, a Novel Drug Candidate for Prader-Willi Syndrome

Retrieved on: 
Tuesday, June 20, 2023
Polyphagia, Obesity, Food, International, Prevalence, McCandless, Metabolism, Stanford University, Colorado Children's Chorale, Quality of life, Hope, Neurodevelopmental disorder, Prader–Willi syndrome, Children's Hospital, NIH Intramural Research Program, Trial of the century, Children's Hospital Colorado, CCK, MD, Patient, SAN, Diabetes, Cholecystokinin, Hospital, PWS, FDA, Therapy, Hunger, Caregiver, Gene, DSM-IV codes, Safety, Pharmaceutical industry, Aardvark, Genetics, Endocrinology

The FDA granted Aardvark Orphan Drug Designation for the use of ARD-101 in Prader-Willi Syndrome (PWS), a rare genetic disease characterized by extreme and unabating hunger.

Key Points: 
  • The FDA granted Aardvark Orphan Drug Designation for the use of ARD-101 in Prader-Willi Syndrome (PWS), a rare genetic disease characterized by extreme and unabating hunger.
  • SAN DIEGO, June 20, 2023 /PRNewswire/ -- Aardvark Therapeutics, Inc., a clinical stage biopharmaceutical company, today reported receipt of an Orphan Drug Designation from the FDA for its lead program, ARD-101, an oral small molecule bitter taste receptor (TAS2R) agonist.
  • Thus far, no drug has been approved by the FDA to treat the hyperphagia associated with PWS.
  • We are so pleased to see the FDA grant Orphan Drug Designation to ARD-101 in recognition of its therapeutic potential based on the promising early clinical findings".

Bidtellect Predicts Top 10 Holiday Campaign Trends for Brands and Advertisers

Retrieved on: 
Wednesday, October 5, 2022
Advertising, Aardvark, Goal, GLOBE, DSP, KPI-driven code analysis, Video, EMarketer, CEO, Solution, Tourism, Public relations, Risk management, Sales

DELRAY BEACH, Fla., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Holiday shopping and consumer spending creep forward every year; Bidtellect , a leading demand-side platform and advertising technology company, urges brands to get holiday campaign strategies in place early.

Key Points: 
  • DELRAY BEACH, Fla., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Holiday shopping and consumer spending creep forward every year; Bidtellect , a leading demand-side platform and advertising technology company, urges brands to get holiday campaign strategies in place early.
  • In their newest resource for performance marketers, Bidtellect predicts the top 10 trends for the 2022 holiday season.
  • "2021 saw the biggest jump in holiday spending in 20 years, according to eMarketer," said Lon Otremba, CEO of Bidtellect.
  • "We're excited for brands and advertisers in what is sure to be a successful holiday season, and we're eager to support our Bidtellect clients in achieving their performance goals," concluded Otremba.

Bidtellect Offers CTV/OTT Advertising Solutions for Improved Bidding, Targeting and Optimization

Retrieved on: 
Wednesday, September 7, 2022
Aardvark, CEO, OTT, Advertising, EMarketer, CTV, DSP, Solution, Smart TV, Goal, GLOBE, KPI-driven code analysis, Population, ROI, Algorithm, Industry, Context, Metadata, Comparison of multi-paradigm programming languages, SSPS, Mobile phone, Sales

Users will be able to leverage Bidtellect's unique and unmatched performance bidding and optimization technology to seamlessly incorporate CTV/OTT into their media buying strategy.

Key Points: 
  • Users will be able to leverage Bidtellect's unique and unmatched performance bidding and optimization technology to seamlessly incorporate CTV/OTT into their media buying strategy.
  • Benefits of Bidtellect's solution include:
    Leveraging the company's cost-efficient bidding capabilities, especiallyAutomatic Algorithmic Rate Determination (AARDvark), which is now available in CTV/OTT.
  • Our range of proprietary contextual, targeting and optimization technology drives KPIs for more efficient delivery of ads."
  • Bidtellect is a performance-driven DSP specializing in context-first optimization, cookieless solutions, and native programmatic.

Bidtellect Shares Digital Advertising Guide for Brands Ahead of Back-to-School Season

Retrieved on: 
Thursday, August 18, 2022
DSP, Aardvark, Solution, Advertising, CEO, ROI, GLOBE, KPI-driven code analysis, Student, Marketing, Technology, Online shopping

Bidtellect , a leading demand-side platform and advertising technology company, is offering assistance on technology and marketing with its Back-to-School Digital Strategy Guide .

Key Points: 
  • Bidtellect , a leading demand-side platform and advertising technology company, is offering assistance on technology and marketing with its Back-to-School Digital Strategy Guide .
  • Bidtellect's guide offers brands vital information to reach those shoppers, including insights on spending trends, the significance of discounts and deals and the overarching benefits of video advertisements.
  • "The pandemic saw a huge jump in e-commerce sales, especially when it came to back-to-school and retail in general," said Lon Otremba, CEO of Bidtellect.
  • Brands can also leverage Bidtellect's contextual targeting technology to reach consumers already researching back-to-school deals and products.

Bidtellect Taps Peer39 for Contextual Keyword Integration

Retrieved on: 
Tuesday, May 24, 2022
Solution, Natural language processing, IAS, Partnership, Aardvark, DSP, Industry, Brand safety, Technology, NLP, Attention, Ecosystem, Machine learning, KPI-driven code analysis, Classification, GLOBE, Satellite navigation device, Public relations, Video

Peer39 is the leading global provider of pre-bid keyword, contextual, and brand safety solutions for modern marketers.

Key Points: 
  • Peer39 is the leading global provider of pre-bid keyword, contextual, and brand safety solutions for modern marketers.
  • Along with keyword targeting and blocking through Peer39, Bidtellect users can also target Peer39 categories and make use of their Brand Safety tools.
  • After considering other contextual keyword integration partners, Bidtellect found that Peer39 offers the highest-quality and sophisticated contextual data and targeting technology in the industry, and is a recognizable addition to Bidtellect's performance-driven platform engine.
  • Peer39 joins Bidtellect's revamped keyword targeting offering that includes Bidtellect's own custom keyword solution in addition to ADmantX by IAS.

Noodles & Company Furthers Its Sustainability Commitment With New Initiative

Retrieved on: 
Monday, January 24, 2022
EU, Woman, Love, Diversity, Noodles & Company, Love Life & Pakodi, Spiral vegetable slicer, NASDAQ, BPI, Female, The Last Best Place, Forbes, Goal, Culture, American City Business Journals, Food, Noodle, Water, Heel, Multiculturalism, Multimedia, FDA, Restaurant, Fast food, Company, Aardvark

"Hoffmasteris proud to partner with Noodles & Co. to help them achieve their sustainability goals," saysHoffmasterPresident AndyRomjue.

Key Points: 
  • "Hoffmasteris proud to partner with Noodles & Co. to help them achieve their sustainability goals," saysHoffmasterPresident AndyRomjue.
  • "By switching from plastic straws to Aardvark Paper Straws, Noodles is demonstrating its commitment to sustainability and helpingaddressour planet's single-use plastic problem."
  • Since 1995, Noodles & Company has been serving noodles your way, with noodles and flavors that you know and love as well as new ones you're about to discover.
  • From indulgent Wisconsin Mac & Cheese to better-for-you Zoodles and Other Noodles, the company serves a world of flavor in every bowl.

AARDVARK THERAPEUTICS, INC., ANNOUNCES IT HAS BEEN INVITED TO PRESENT AT THE 40th ANNUAL J.P. MORGAN HEALTH CARE CONFERENCE

Retrieved on: 
Monday, January 10, 2022
Conference, Intention, SAN, Inflammation, Weight loss, Appetite, Lists of diseases, Safety, Volunteering, Obesity, Therapy, Hyperlipidemia, Diabetes, Aardvark, Polyphagia, Pharmaceutical industry

Aardvark proudly announces that it has received an invitation to present at the 40th annual J.P. Morgan Healthcare Conference on January 13th, 2022.

Key Points: 
  • Aardvark proudly announces that it has received an invitation to present at the 40th annual J.P. Morgan Healthcare Conference on January 13th, 2022.
  • In addition, the company will be presenting in January at the 2022 Biotech Showcase and the 2022 HC Wainwright BIOCONNECT Conference.
  • Importantly, a First-in-Human Phase 1 study confirmed ARD-101's favorable safety profile and pharmacodynamic activities and Phase 2 studies have commenced.
  • Aardvark Therapeutics CEO, Tien Lee, M.D., commented: "Aardvark has made tremendous progress demonstrating ARD-101's unique activity in multiple animal models of metabolic and inflammatory disease.

Bidtellect Saves 35% on Bidstream Processing Costs Using BidSwitch

Retrieved on: 
Thursday, October 14, 2021
Goal, Solution, DSP, Advertising, Technology, History, SSP, Industry, Aardvark, Engineering, Norris Production Solutions, Marketing, GLOBE, DOOH, ROI, KPI-driven code analysis, Auction, Risk management

Bidtellect is a buy-side platform that helps brand advertisers reach targeted audiences in contextually relevant environments at scale across the web.

Key Points: 
  • Bidtellect is a buy-side platform that helps brand advertisers reach targeted audiences in contextually relevant environments at scale across the web.
  • Bidtellect turned to BidSwitch to manage some of its over 40 connections to SSP partners, leaning on BidSwitchs SmartSwitch to filter out unwanted inventory, reducing the costs associated with listening to huge volumes of bidstream data and helping Bidtellect improve the overall bidding performance for their clients.
  • To further help buy-side effectiveness, Bidtellect recently announced AARDvark (Automatic Algorithmic Rate Determination), its proprietary automatic bid factoring technology.
  • BidSwitchs SmartSwitch technology applies proprietary machine learning to the global programmatic bidstream that BidSwitch processes daily from more than 130 supply partners.